bDMARDs and other specialised medicines have made a significant improvement in the management of chronic diseases like inflammatory arthritis, inflammatory bowel disease and dermatological conditions. These medicines are part of the fastest‐growing sector of the pharmaceutical market yet are complex for consumers, specialists and pharmacists to navigate.
With funding from the Australian Government Department of Health, NPS MedicineWise and a range of organisations representing specialists, pharmacists, consumers and research experts have formed the Targeted Therapies Alliance. The aim of the Alliance is to provide stewardship and direction about the safe and wise use of bDMARDs and other specialised medicines to ensure the best possible health and economic outcomes.
Video: Value in Prescribing bDMARDS Program and the Targeted Therapies Alliance
NPS MedicineWise CEO Associate Professor Steve Morris and ARA President and rheumatologist Professor Catherine Hill introduce the bDMARDs program.
The Targeted Therapies Alliance has developed resources, tools and interventions in line with the latest evidence to empower consumers, specialists, pharmacists, nurses, hospitals, and drug and therapeutics committees to make safe and wise therapeutic decisions about bDMARDs and other specialised medicines.
NPS MedicineWise and the organisations who make up the Alliance will publish specific information about the use of biological and other specialised medicines across a range of rheumatology, dermatology and gastroenterology conditions. This will include, for example, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn disease and ulcerative colitis.
Access to the information developed by organisations who make up the Alliance will be promoted and made available through this website and through Alliance members’ websites.
The first area of focus is rheumatology and an initial range of content and resources is available from November 2020.
The Alliance is currently working closely with dermatology and gastroenterology professional and consumer organisations to design and develop resources and materials for these conditions, and these will be available from early 2021.
About the Targeted Therapies Alliance
Funded by the Australian Government Department of Health through the Value in Prescribing – Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) Program Grant, the consortium is led by NPS MedicineWise and includes nine organisations representing specialists, pharmacists, consumers and research experts .
- Arthritis Australia
- Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network
- Australian Rheumatology Association
- Cochrane Musculoskeletal
- Council of Australian Therapeutic Advisory Groups
- NPS MedicineWise
- Pharmaceutical Society of Australia
- Quality Use of Medicines and Pharmacy Research Centre (University of South Australia)
- Society of Hospital Pharmacists of Australia
The consortium also works closely with the key dermatology and gastroenterology organisations,
The Australasian College of Dermatologists, Psoriasis Australia, Gastroenterological Society of Australia and Crohn’s & Colitis Australia.
Useful NPS MedicineWise resources
Australian Prescriber: an independent peer-reviewed journal providing critical commentary on drugs and therapeutics for health professionals
Choosing Wisely: a global health initiative that is enabling clinicians, consumers and healthcare stakeholders to start important conversations about tests, treatments and procedures, where evidence shows they provide no benefit, or in some cases, lead to harm.
RADAR: timely, independent, evidence-based information for health professionals on new drugs and medical tests and changes to listings on the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule.
MedicineWise app: enabling consumers to keep track of medicines and access important health information. Funded by the Department of Health
Targeted Therapies Alliance media releases
- Finding safe, effective treatments for inflammatory bowel disease
16 June 2021
- Biologics, biosimilars and PBS sustainability
21 May 2021
- Supporting best use of specialised medicines for inflammatory bowel disease
07 May 2021
- Keeping rheumatoid arthritis in check – start early to save your joints
16 Dec 2020
- New resources to support down-titration of b/tsDMARDs
03 Nov 2020
- PBS Practice Review – The role of bDMARDs in the management of rheumatoid arthritis
13 Oct 2020
- A new approach to support specialist prescribing of bDMARDs
17 Sep 2019
Information, tools and resources for optimising safety and health outcomes in your use of bDMARDs for patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis .
Information, tools and resources for optimising safety and health outcomes in your use of biological and other specialised medicines for patients with inflammatory bowel disease (IBD).
Information, tools and resources for optimising safety and health outcomes in your use of biological and other specialised medicines for patients with plaque psoriasis.
Biologics and biosimilars
Tools and information to explain how biological medicines and their biosimilars are approved and funded for use in Australia, how prices are determined and reviewed over time, the impact of biosimilars and how to talk to your patients about biosimilars.